Lumida
/FULC
⌘K
Fulcrum Therapeutics Inc

Fulcrum Therapeutics Inc

FULC
$3.65USD+4.29%+0.15 today

MARKET CAP

243.2M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $4

52W RANGE

$3
$16

AI Summary

Stalk
TrimMedium

FULC remains in Stage 4 decline with a clear lower-high/lower-low sequence under declining EMAs and price confined below the 9EMA/21EMA region. A terminal Double Bottom suggests exhaustion, but without confirmed EMA repair or a higher high, bearish control persists. The recommended posture is to trim into any rally toward the overhead EMA zone. A sustained close and follow-through above the 21EMA would invalidate this bearish bias.

  • Phase 1B Pioneer trial: HbF from 7.1%→19.3% at week 12, reducing vaso-occlusive crises.
  • $333.3M cash on hand sustains trials and operations into 2029.
  • Q1 2026 net loss widened to $22.2M from $20.4M year-ago.
Full analysis →
Insider Trades6 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Dec 15, 2025SellFULCCurtis Gale OltmansChief Legal Officer3,452$12.92$243.2M-76.81%+28.98%$44.6K-25.19%10b5-1Trim
May 8, 2025SellFULCGreg TourangeauPrincipal Accounting Officer498$5.06$243.2M-76.81%+28.98%$2.5K-3.42%Trim
Jul 3, 2024BuyFULCAlex Sapir150,000$3.27$243.2M-76.81%+28.98%$490.5K+6.46%Trim
May 7, 2024SellFULCGreg TourangeauPrincipal Accounting Officer236$7.76$243.2M-76.81%+28.98%$1.8K-2.00%Trim
Mar 8, 2024SellFULCGreg TourangeauVice President, Finance4,884$11.72$243.2M-76.81%+28.98%$57.2K-29.26%Trim
Mar 4, 2024BuyFULCAlex Sapir43,360$11.35$243.2M-76.81%+28.98%$492.0KTrim